Kim J-M, Stewart R, Lee Y-S, Lee H-J, Kim MC, Kim J-W, Kang H-J, Bae K-Y, Kim S-W, Shin I-S, Hong YJ, Kim JH, Ahn Y, Jeong MH, Soon J-S. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome. A randomized clinical trial. JAMA 2018;320:350-8. [Ref.ID 102816]

Piller C, You J. Hidden conflicts? Pharma payments to FDA advisers after drug approvals spark ethical concerns. Science 2018:5 de julio. [Ref.ID 102814]

Abdullah SM, Defina LF, Leonard D, Barlow CE, Radford NB, Willis BJ, Rohatgi A, McGuire DK, de Lemos JA, Grundy SM, Berry JD, Khera A. Long-term association of low-density lipoprotein cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease results from the Cooper Center Longitudinal Study. Circulation 2018;138:16 de agosto. [Ref.ID 102796]

Huang W-Y, Singer DE, Wu J-L, Chiang C-E, Weng H-H, Lee M, Ovbiagele B. Association of intracranial hemorrhage risk with non–vitamin K antagonist oral anticoagulant use vs aspirin use. A systematic review and meta-analysis. JAMA Neurology 2018:13 de agosto. [Ref.ID 102795]

Voelker R. Another caution for clarithromycin. JAMA 2018;319:1 de junio. [Ref.ID 102782]

Dahal K, Hendrani A, Sharma SP, Singireddy S, Mina G, Reddy P, Dominic P, Modi K. Aldosterone antagonist therapy and mortality in patients with ST-segment elevation myocardial infarction without heart failure. A systematic review and meta-analysis. JAMA Intern Med 2018;178:julio. [Ref.ID 102774]

Anónimo. Facteurs de croissance granulocytaire (grastims): aortites. Prescrire 2018;38:517. [Ref.ID 102763]

Rothwell PPM, Cook PNR, Gaziano PJM, Price JF, Belch PJFF, Roncaglioni MC, Morimoto T, Mehta Z. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 2018:12 de julio. [Ref.ID 102745]

Bielecka-Dabrowa A, Fabis J, Mikhailidis DP, von Haehling S, Sahebkar A, Rysz J, Banach M. Prosarcopenic effects of statins may limit their effectiveness in patients with heart failure. Trends Pharmacol Sci 2018;39:abril. [Ref.ID 102681]

Yadlowsky S, Hayward RA, Sussman JB, McClelland RL, Min YI, Basu S. Clinical implications of revised pooled cohort equations for estimating atherosclerotic cardiovascular disease risk. Ann Intern Med 2018;169:20-9. [Ref.ID 102647]

Adderley NJ, Nirantharakumar K, Marshall T. Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies. BMJ 2018;360:9 de mayo. [Ref.ID 102644]

Park Y, Bateman BT, Kim DH, Hernandez-Diaz S, Patorno E, Glynn RJ, Mogun H, Hyubrechts KF. Use of haloperidol versus atypical antipsychotics and risk of in-hospital death in patients with acute myocardial infarction: cohort study. BMJ 2018;360:28 de marzo. [Ref.ID 102642]

Tsourdi E, Rachner TD, Hofbauer LC. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102629]

Lewis JR, Schousboe JT, Prince RL. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102628]

Song GG, Lee YH. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102627]

Anónimo. Edoxaban: Interstitial lung disease. Japan . WHO Drug Information 2018;32:18. [Ref.ID 102620]

Malhotra K, Katsanos AH, Bilal M, Ishfaq MF, Goyal N, Tsivgoulis G. Cerebrovascular outcomes with proton pump inhibitors and thienopyridines. Stroke 2018;49:febrero. [Ref.ID 102619]

Pylypchuk R, Wells S, Kerr A, Poppe K, Riddell T, Harwood M, Exeter D, Mehta S, Grey C, Wu BP, Metcalf P, Warren J, Harrison J, Marshall R, Jackson R. Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study. Lancet 2018;391:12 de mayo. [Ref.ID 102612]

Chen TT, Yeh YC, Chien KL, Lai MS, Tu YK. Risk of infective endocarditis after invasive dental treatments: a case-only study. Circulation 2018:19 de abril. [Ref.ID 102607]

Kamali KN, Lloyd-Jones DM, van der Leeuw J, Goff Jr DC, Yusuf S, Zanchetti A, Glasziou P, Jackson R, Woodward M, Rodgers A, Neal BC, Berge E, Teo K, Davis BR, Chalmers J, Pepine C, Rahimi K, Sundström J, on behalf of the Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data. PLOS Medicine 2018:20 de marzo. [Ref.ID 102591]